3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
5
Uterine Cervical Neoplasms
2
Oropharyngeal Neoplasms
2
Hodgkin Disease
2
Cholangiocarcinoma
2
Carcinoma, Hepatocellular
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Paraganglioma
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma
1
Melanoma
1
Lymphoma, T-Cell
1
Lymphoma, Mantle-Cell
1
Lung Neoplasms
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Leukemia, Plasma Cell
1
Glioma
1
Disease
1
Carcinoma, Squamous Cell
1
Interventions
Magnetic Resonance Spectroscopy
4
Specimen Handling
3
Nivolumab
3
ulixertinib
2
binimetinib
2
Ipilimumab
2
Immunoglobulin G
2
Disulfides
2
Cetuximab
2
CTLA-4 Antigen
2
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
trametinib
1
tipifarnib
1
temsirolimus
1
selpercatinib
1
sapanisertib
1
repotrectinib
1
relatlimab
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
larotrectinib
1
ipatasertib
1
erdafitinib
1
defactinib
1
dabrafenib
1
copanlisib
1
capivasertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Thyroid Neoplasms
×
Fluorodeoxyglucose F18
×
30 days
×
Clear all
No trials found.